Nilotinib, a BCR-ABL tyrosine kinase inhibitor, has been investigated in multiple cases as a medication against mental disorders, such as Parkinson’s disease and Alzheimer’s disease [109,110]. The gene discussed is ABL1; the disease is Parkinson disease.